« Back
Home /
Tubastatin A (Hydrochloride)

Tubastatin A (Hydrochloride)

Item no.	HY-13271-50mg
Manufacturer	MedChem Express
CASRN	1310693-92-5
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Epigenetics Inhibitors & Compound Libraries Small Molecules By Organ Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Purity	99.31
Citations	[1]Kyle V. Butler et al. Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A J. Am. Chem. Soc., 2010, 132 (31), pp 10842-10846\|[2]de Zoeten EF, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011 May;31(10):2066-78.\|[3]Di Fulvio S, et al. Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One. 2011;6(12):e28563\|[4]Ketene AN, et al. Actin filaments play a primary role for structural integrity and viscoelastic response in cells. Integr Biol (Camb). 2012 May;4(5):540-9.\|[5]Brijmohan AS, et al. HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease. Front Pharmacol. 2018 Feb 1;9:34.\|[6]Severin Lechner, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Apr 28. Atherosclerosis. 2021 Jan;317:1-9.\|Cell Death Dis. 2022 Oct 21;13(10):888.\|Front Pharmacol. 2018 Feb 1;9:34.\|Hum Mol Genet. 2022 Jan 12;ddac008.\|J Biomed Sci. 2025 Jan 20;32(1):9.\|Neurotherapeutics. 2023 Jun 2.\|PLoS Pathog. 2021 Sep 20;17(9):e1009940.\|Acta Pharm Sin B. 20 May 2022.\|Aging. 2021 Mar 19;13(7):9820-9837.\|Am J Pathol. 2020 Dec;190(12):2376-2386.\|Antioxidants (Basel). 2022 Apr 7;11(4):732.\|Antioxidants. 2020 Jul 9;9(7):599.\|Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118676.\|bioRxiv. 2021 Feb 25.\|bioRxiv. 2025 January 31.\|BMC Biol. 2018 Oct 18;16(1):116.\|Clin Transl Med. 2025 Jan;15(1):e70193.\|J Dermatol Sci. 2022 May 17;S0923-1811(22)00125-6.\|J Med Chem. 2023 Nov 16.\|J Med Chem. 2024 Aug 15.\|J Mol Neurosci. 2024 Mar 13.\|J Nutr. 2020 Jul 1;150(7):1790-1798.\|Medical Science, University of Toronto. 2017 Nov.\|Mol Cancer Res. 2014 May;12(5):681-93.\|Mol Cancer Res. 2022 Mar 4;molcanres.0923.2021.\|Neurotherapeutics. 2023 Jun 2.\|NPJ Precis Oncol. 2024 Mar 7;8(1):66.\|Patent. US20180263995A1.\|Viruses. 2025 Jan 13;17(1):90.
Smiles	O=C(C1=CC=C(C=C1)CN2C3=C(C4=C2C=CC=C4)CN(C)CC3)NO.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Tubastatin A HCl,TSA HCl
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Autophagy; Beta-lactamase; HDAC
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	371.86
Product Description	Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
Manufacturer - Research Area	Cancer
Solubility	DMSO: 10.8 mg/mL (ultrasonic; warming)\|H2O: 6.67 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics
Isoform	HDAC1; HDAC6; HDAC8
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13271-50mg-safety-datasheet.pdf